AD
Therapeutic Areas
Attralus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pan-Amyloid Depleter (Lead PAR Therapeutic) | Systemic Amyloidosis (all types: ATTR, AL, AA, etc.) | Phase 1/2 |
| Pan-Amyloid Diagnostic Imaging Agent | Diagnosis and Staging of Systemic Amyloidosis | N/A (Diagnostic) |
Leadership Team at Attralus
MT
Mark Timney
Chief Executive Officer
GF
Glen Firestone
Chief Business Officer
GB
Gregory Bell
Chief Medical Officer
NA
Nicolas Angell
Vice President, CMC
JT
James Testa
Vice President, Finance
KR
Karen Robertson
Vice President, Regulatory Affairs
KG
Krishna Gorti
Head of Corporate Development
CH
Christine Huh
Head of Human Resources
JW
Jonathan Wall
Co-Founder & Interim Chief Scientific Officer
CG
Corey Goodman
Managing Partner, venBio (Board of Directors)